Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB Double Blind, Randomized, Placebo Controlled Clinical Trial to Determine the Pharmacokinetics and Safety of a Revised Protocol of Intravenous L-Citrulline (Citrupress®) Versus Placebo in Children Undergoing Cardiopulmonary Bypass

NCT01120964 is registered in ClinicalTrials.gov with Asklepion Pharmaceuticals, LLC as lead sponsor.

NCT NCT01120964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01120964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB Double Blind, Randomized, Placebo Controlled Clinical Trial to Determine the Pharmacokinetics and Safety of a Revised Protocol of Intravenous L-Citrulline (Citrupress®) Versus Placebo in Children Undergoing Cardiopulmonary Bypass
Lead sponsor
Asklepion Pharmaceuticals, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2010
Completion date
April 30, 2012
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atrial septal defect, atrioventricular septal defect, ventricular septal defect